These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 5577947)

  • 21. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
    Hájek R; Adam Z; Vásová I; Král Z
    Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Maintenance therapy with low-dose of melphalan in multiple myeloma (author's transl)].
    Hirasawa Y; Nagaoka T; Kuto F; Tokuhiro H; Kikawada R
    Rinsho Ketsueki; 1980 Nov; 21(11):1646-54. PubMed ID: 7206225
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical study on chemotherapy for multiple myeloma. Part II: Prognostic factors of treatment with prednisolone and sequential melphalan and ifosfamide: MIP therapy].
    Sezaki T; Ishii H; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):433-9. PubMed ID: 6887543
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 30. [Primary treatment results in myeloma disease using a cytostatic preparation].
    Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
    Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
    [No Abstract]   [Full Text] [Related]  

  • 31. [TREATMENT OF KAHLER'S DISEASE WITH MELPHALAN].
    DIK HJ; DE VRIES SI
    Ned Tijdschr Geneeskd; 1964 Jul; 108():1343-8. PubMed ID: 14183530
    [No Abstract]   [Full Text] [Related]  

  • 32. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone].
    Sezaki T; Ishii H; Osada T; Adachi T; Takahashi I; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1982 Jun; 23(6):847-53. PubMed ID: 7176091
    [No Abstract]   [Full Text] [Related]  

  • 37. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
    Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
    Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293
    [No Abstract]   [Full Text] [Related]  

  • 38. [Letter: Myeloma and myelo-monocytic leukemia. Role of melphalan].
    Marsan C; Henon P; Quillard A; Grimaldi A; Cywiner-Golener C
    Nouv Presse Med; 1973 Dec; 2(44):2958. PubMed ID: 4521337
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R
    Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
    Scolozzi R; Boccafogli A
    Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.